文献速递生殖医学产科

2016年中国大陆辅助生殖技术服务的可及性、有效性和安全性

Assisted reproductive technology service availability, efficacy and safety in mainland China: 2016.
PubMed 文献 · Hum Reprod · 2020-01-01

该研究为2018年完成的全国横断面调查,收集2016年中国大陆31个省份445家ART诊所的治疗数据。ART服务可及性较前改善,但地区间不均衡,主要有效性和安全性指标接近西方国家水平。

要点

  • 2016年中国大陆ART周期数达每百万人口657个,较2013年的360个增加,但省份间差异大(45-3676)。
  • 常规IVF每取卵周期临床妊娠率23.2%、分娩率18.7%,双胎分娩占比27.9%;ICSI分别为20.5%、16.7%、27.2%。
  • 冻融胚胎移植每解冻周期妊娠率48.2%、分娩率37.6%;中重度OHSS发生率为每1000取卵周期11.5例。

核心结论

  • 2016年中国大陆ART服务可及性显著提高,但地区间服务提供存在明显不均衡,主要有效性和安全性指标接近西方国家水平。

研究设计与样本

  • 2018年完成的一项全国横断面调查,收集2016年1月1日至12月31日中国大陆31个省份445家ART诊所的服务数据。
  • 2016年大陆共有451家持牌ART诊所(含人工授精诊所),其中445家提交了服务数据。

主要发现

  • 中重度OHSS发生率为每1000取卵周期11.5例,其他并发症更罕见。

关键数值与推荐

  • 常规IVF每取卵周期临床妊娠率23.2%、分娩率18.7%,双胎分娩占全部分娩的27.9%。
  • ICSI每取卵周期临床妊娠率20.5%、分娩率16.7%、双胎分娩率27.2%。
  • FET每解冻周期临床妊娠率48.2%、分娩率37.6%、双胎分娩率24.2%。
  • PGD每诊断周期临床妊娠率38.1%、分娩率29.7%、双胎分娩率4.2%。
  • AIH临床妊娠率13.3%、分娩率10.5%;AID临床妊娠率24.3%、分娩率21.1%。

临床怎么用

  • 了解中国大陆ART服务可及性及各省份差异,为服务规划和资源配置提供依据。
  • 参考各ART技术的妊娠率、分娩率和双胎率指标,用于临床咨询和质量评估。
  • 关注中重度OHSS发生率,加强取卵周期并发症监测。

局限性

  • 报告基于ART服务汇总数据,成功率未按年龄分层计算。
  • 报告的出生缺陷率较低,可能受出生随访方法、统计时机和记录差异影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the current status of assisted reproductive technology (ART) service availability, efficacy and safety in mainland China? SUMMARY ANSWER: In this first national report on ART status in mainland China, data on treatment numbers, outcomes and complications in 2016 are provided and analyzed, respectively. WHAT IS KNOWN ALREADY: National ART Service Provision Surveys are conducted in mainland China regularly. Data were analyzed, and this manuscript was written by team members from the National Center for Women and Children's Health, China CDC and the Department of Women and Children Health, National Health Commission of the People's Republic of China. STUDY DESIGN, SIZE AND DURATION: A cross-sectional nationwide survey was completed in 2018, in which data regarding ART treatments, performed from 1st January to 31st December2016 in 445 ART clinics located in 31 provinces of mainland China, were collected. PARTICIPANTS/MATERIALS, SETTING AND METHODS: There were in total 451 licensed ART clinics (including artificial insemination clinics) in mainland China in 2016, of which 445 submitted service data. A total of 906 840 cycles were provided by 323 in vitro fertilization (IVF) clinics, involving 375 770 conventional IVF cycles, 154 948 intracytoplasmic sperm injection (ICSI) cycles, 367 146 frozen embryo transfer (FET) thawing cycles and 8976 preimplantation genetic diagnosis (PGD) treatment cycles. A total of 161 376 artificial (i.e. intrauterine) insemination (AI) cycles were reported by 443 clinics, with 126 872 cycles using the husband's semen (AIH) and 34 504 using donor semen (AID). MAIN RESULTS AND THE ROLE OF CHANCE: In total, 98.7% of the licensed clinics, contributing to 100% of the ART services (including AID and AIH cycles), were included in this report. (Six clinics provided institutional information only and were excluded.) There were 906 840 in vitro fertilization cycles performed in mainland China with a population of over 1.3 billion inhabitants, with cycles per million inhabitants (C/M) increasing from 360 in 2013 to 657 in 2016, nationwide (range among provinces: 45-3676). After treatment with conventional IVF, the clinical pregnancy rate (PR) per oocyte retrieval cycle was 23.2%, the delivery rate (DR) per oocyte retrieval cycle was 18.7% and the proportion of twin delivery among the total deliveries was 27.9%. For ICSI cycles, the PR, DR and TDR were 20.5%, 16.7% and 27.2%, respectively. For FET per thawing cycles, the PR, DR and TDR were 48.2%, 37.6% and 24.2%. For PGD per diagnosis cycles, the PR, DR and TDR were 38.1%, 29.7% and 4.2%. For AIH cycles, the PR and DR were 13.3% and 10.5%; for AID cycles, the PR and DR were 24.3% and 21.1%, respectively. The total number of live infants born in mainland China in 2016, was 18.46 million, and the number of infants born through ART conducted in 2016 was 311 309, which accounted for 1.69% of the total. The reported rate of birth defects was about 87/10 000. The incidence of moderate to severe ovarian hyper-stimulation syndrome (OHSS) was 11.5 per 1000 oocyte retrieval cycles, and other complications were much more rare. LIMITATIONS AND REASONS FOR CAUTION: This report is based on the summary data of ART services provided. The success rates were not calculated by age stratification. A low rate of birth defects was reported, which might be confounded by variations in birth follow-up methods, statistical timing and record taking. WIDER IMPLICATIONS OF THE FINDINGS: ART service availability has improved significantly in recent years in mainland China. Because China is a vast country, significant imbalances in ART service provision do exist; however, the main efficacy and safety indicators were close to those of western countries. TRIAL REGISTRATION NUMBER: N/A. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by the National Key R&D Program of China (2016YFC1000307-2). There are no competing interests.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Bai F, Wang DY, Fan YJ, et al. Assisted reproductive technology service availability, efficacy and safety in mainland China: 2016. Hum Reprod. 2020. PMID: 32020190. doi:10.1093/humrep/dez245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。